Eli Lilly Stock Drops Despite Positive Analyst Outlook
Eli Lilly's stock fell 2.5% on April 21, 2026, despite a positive analyst rating from UBS. The drop followed the company's $7 billion acquisition of Kelonia Therapeutics for a CAR-T gene therapy drug, which investors viewed as a diversification move away from its reliance on GLP-1 drugs.
Tickers: $LLY
Topics: acquisition analyst opinion CAR-T gene therapy Eli Lilly GLP-1 drugs stock price